Decreased bone density, elevated serum osteoprotegerin, and β-cross-laps in Wilson disease

Journal of Bone and Mineral Research

Volumn 17, Issue 11, 2002, Pages 1961-1967

  Hegedus, D ^a   Ferencz, V ^a   Lakatos, P L ^a   Meszaros, S ^a   Lakatos, P ^a   Horvath, C ^a   Szalay, F ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Osteocalcin; Osteoprotegerin; RANKL; Wilson disease; cross laps

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CERULOPLASMIN; GAMMA GLUTAMYLTRANSFERASE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; MALE; OSTEOCLAST; OSTEOPENIA; OSTEOPOROSIS; SERUM; WILSON DISEASE;

EID: 0036830092     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.11.1961     Document Type: Article

References (39)

1. Finby N, Bearn AG 1958 Roentgenographic abnormalities of the skeletal system in Wilson's disease (hepatolenticular degeneration). Am J Roentgen 79:603-611.
2. Rosenoer VM, Michell RC 1959 Skeletal changes in Wilson's disease (hepatolenticular degeneration). Br J Radiol 32:805-809.
3. Mindelzung R, Elkin M, Scheinberg HI, Sternlieb I 1970 Skeletal changes in Wilson's disease: A radiological study. Radiology 94:127-132.
4. Aksoy M, Camli N, Dincol K, Erdem S, Akgun T 1972 Osseous changes in Wilson's disease: A radiologic study of nine patients. Radiology 102:505-509.
5. Yu-zhang X, Xue-zhe Z, Xian-hao X, Zhen-xin Z, Ying-kun F 1985 Radiologic study of 42 cases of Wilson disease. Skeletal Radiol 13:114-119.
6. Garnero P, Grimaux M, Demiaux B, Préaudat C, Séguin P, Delmas PD 1992 Measurement of serum osteocalcin with a human specific two-site-radioimmunoassay. J Bone Miner Res 7:1389-1397.
7. Kohsla S, Kleerekoper M 1999 Biochemical markers of bone turnover. In: Favus MJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th Ed. Lippincott Williams & Wilkins, Philadelphia, PA, USA, pp. 128-134.
8. Garnero P, Gineyts E, Riou JP, Delmas PD 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785.
9. Hofbauer LC 1999 Ostoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 141:195-210.
10. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
11. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E 2002 Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2:233-238.
12. Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A 2001 Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 30:229-234.
13. Ueland T, Bollerslev J, Godang K, Müller F, Froland SS, Aukrust P 2001 Increased serum osteoprotegerin level in disorders characterized by persistent immune activation or glucocorticoid excess - Possible role in bone homeostasis. Eur J Endocrinol 145:685-690.
14. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E 2001 Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 10:2977-2983.
15. Szalay F, Hegedus D, Lakatos PL, Bajnok E, Dunkel K, Lakatos P 2002 High serum osteoprotegerin and low RANKL levels in primary biliary cirrhosis. J Hepatol (in press).
16. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M, Nordic Myeloma Study Group 2001 Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98:2269-2271.
17. Kaufman JJ, Einhom TA 1993 Ultrasound assessment of bone. J Bone Miner Res 8:517-525.
18. Roux C, Fournier B, Laugier P, Chappard C, Kolta S, Dougados M, Berger G 1996 Broadband ultrasound attenuation imaging: New imaging method in osteoporosis. J Bone Miner Res 11:1112-1118.
19. He YQ, Fan B, Hans D, Li J, Wu CY, Njeh CF, Zhao S, Lu Y, Tsuda-Futami E, Fuerst T, Genant HK 2000 Assessment of a new quantitative ultrasound calcaneus measurement: Precision and discrimination of hip fractures in elderly women compared with dual x-ray absorptiometry. Osteoporos Int 11:354-360.
20. Firneisz G, Lakatos PL, Szalay F, Polli C, Glant TT, Ferenci P 2001 Common mutations of ATP 7B in Wilson disease patients from Hungary. Am J Med Genet 108:23-28.
21. Osteoporosis Task Force 2001 American Association of Clinical Endocrinologists. 2001 Medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 7:293-312.
22. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N 1994 The diagnosis of osteoporosis. J Bone Miner Res 8:1137-1141.
23. Frost ML, Blake M, Fogelman I 2000 Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporos Int 11:321-330.
24. Glüer CC for the International Quantitative Ultrasound Consensus Group 1997 Quantitative ultrasound techniques for the assessment of osteoporosis: Expert agreement on current status. J Bone Miner Res 12:1280-1288.
25. Menery KA, Eider W, Brewer GJ, Brauenstein EM, Schumacher HR, Fox IH 1988 The arthropathy of Wilson's disease. J Rheumatol 15:331-337.
26. Morgan HG, Stewart WK, Lowe KG, Stowers JM, Johnstone JH 1962 Wilson's disease and the Fanconi syndrome. Q J Med 31:361-384.
27. Tallis GA, Kitchener MI, Thomas AC 1990 Hyperparathyroidism in a patient with Wilson's disease. Clin Chem 36:568-570.
28. Simonet WS, Lacely DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
29. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moor G, Truneh A 1997 Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204:35-46.
30. Yasuda H, Shima N, Nakagawa N, Mochizuki S-I, Yano K, Fijuse N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): Mechanism by which OPG/OCIF inhibits osteogenesis in vitro. Endocrinology 139:1329-1337.
31. Lacely DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
32. Tsuda E, Goto M, Mochizuki S-I, Yano K, Kobayashi F, Morinaga T, Higashio K 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142.
33. Emery JG, McDonnell P, Brigham Burke M, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:1463-1467.
34. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
35. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III, Frankel WN, Lee SY, Choi Y 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194.
36. Anderson MA, Maraskovsky E, Billingsley WL, Dougal WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179.
37. Hsu H, Lacely DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545.
38. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400.
39. Auld DS 1995 Removal and replacement of metal ions in metallopeptidases. Methods Enzymol 248:228-242.